<?xml version="1.0" encoding="UTF-8"?><rss version="2.0"
	xmlns:content="http://purl.org/rss/1.0/modules/content/"
	xmlns:wfw="http://wellformedweb.org/CommentAPI/"
	xmlns:dc="http://purl.org/dc/elements/1.1/"
	xmlns:atom="http://www.w3.org/2005/Atom"
	xmlns:sy="http://purl.org/rss/1.0/modules/syndication/"
	xmlns:slash="http://purl.org/rss/1.0/modules/slash/"
	>

<channel>
	<title>nitrosamine Archives - Focal Point</title>
	<atom:link href="https://focalpointresearch.net/tag/nitrosamine/feed/" rel="self" type="application/rss+xml" />
	<link>https://focalpointresearch.net/tag/nitrosamine/</link>
	<description>Scientific, Regulatory and New Product Consultants</description>
	<lastBuildDate>Thu, 04 Jun 2026 13:49:48 +0000</lastBuildDate>
	<language>en-US</language>
	<sy:updatePeriod>
	hourly	</sy:updatePeriod>
	<sy:updateFrequency>
	1	</sy:updateFrequency>
	<generator>https://wordpress.org/?v=7.1.4</generator>

<image>
	<url>https://focalpointresearch.net/wp-content/uploads/2021/11/cropped-focal_point_chart_03-32x32.jpg</url>
	<title>nitrosamine Archives - Focal Point</title>
	<link>https://focalpointresearch.net/tag/nitrosamine/</link>
	<width>32</width>
	<height>32</height>
</image> 
<site xmlns="com-wordpress:feed-additions:1">126679100</site>	<item>
		<title>Health Canada updates guidance on nitrosamine impurities in medications</title>
		<link>https://focalpointresearch.net/canadian-regulatory/health-canada-updates-guidance-on-nitrosamine-impurities-in-medications/</link>
		
		<dc:creator><![CDATA[Srishti Chaudhari]]></dc:creator>
		<pubDate>Thu, 04 Jun 2026 13:49:46 +0000</pubDate>
				<category><![CDATA[Canadian Quality Assurance]]></category>
		<category><![CDATA[Canadian Regulatory]]></category>
		<category><![CDATA[Health Canada Updates]]></category>
		<category><![CDATA[OTC Drugs]]></category>
		<category><![CDATA[Canadian OTC Drug Regulatory Consultants]]></category>
		<category><![CDATA[Canadian OTC Regulatory Consultants]]></category>
		<category><![CDATA[Canadian Regulatory Consultants]]></category>
		<category><![CDATA[Focal Point Research]]></category>
		<category><![CDATA[FPR]]></category>
		<category><![CDATA[Health Canada]]></category>
		<category><![CDATA[Health Canada consultants]]></category>
		<category><![CDATA[nitrosamine]]></category>
		<category><![CDATA[North American Regulatory Consultants]]></category>
		<category><![CDATA[North American Scientific Regulatory Affairs & Quality Assurance Consulting Firm]]></category>
		<category><![CDATA[OTC Consultants]]></category>
		<category><![CDATA[OTC Drug Consultants]]></category>
		<category><![CDATA[OTC drugs]]></category>
		<category><![CDATA[Regulatory Affairs Consultants]]></category>
		<category><![CDATA[Regulatory Consultants]]></category>
		<category><![CDATA[Scientific Regulatory & New Product Consultants]]></category>
		<guid isPermaLink="false">https://focalpointresearch.net/?p=5866</guid>

					<description><![CDATA[<p>Health Canada has released an updated version of its Guidance on Nitrosamine Impurities in Medications, incorporating several important changes. The summary below applies to Non-Prescription Drugs, chemically synthesized excipients and raw materials used in the manufacturing of drug products. Key updates include: Reporting Requirements: Following confirmatory testing, Market Authorization Holders (MAHs) must assess whether nitrosamine [&#8230;]</p>
<p>The post <a href="https://focalpointresearch.net/canadian-regulatory/health-canada-updates-guidance-on-nitrosamine-impurities-in-medications/">Health Canada updates guidance on nitrosamine impurities in medications</a> appeared first on <a href="https://focalpointresearch.net">Focal Point</a>.</p>
]]></description>
										<content:encoded><![CDATA[
<p class="wp-block-paragraph">Health Canada has released an updated version of its Guidance on Nitrosamine Impurities in Medications, incorporating several important changes. The summary below applies to Non-Prescription Drugs, chemically synthesized excipients and raw materials used in the manufacturing of drug products.</p>



<p class="wp-block-paragraph">Key updates include:</p>



<p class="wp-block-paragraph">Reporting Requirements: Following confirmatory testing, Market Authorization Holders (MAHs) must assess whether nitrosamine impurities exceed the established Acceptable Intake (AI) limit and determine whether market action is required. MAHs are no longer required to notify Health Canada each time an elevated nitrosamine impurity level is detected. Notification is only required when a recall decision has been made, in accordance with the Drug, Natural Health Product and Biocide Recall guide (GUI-0039).</p>



<p class="wp-block-paragraph">Risk Mitigation Expectations: While the guidance maintains a 3-year CAPA implementation timeline, Health Canada expects MAHs to implement risk mitigation measures and reduce nitrosamine levels below AI limits as soon as possible.</p>



<p class="wp-block-paragraph">Safety: New contact information has been added for enquiries regarding applicable Acceptable Intake (AI) limits, including proposal for new AI limits.</p>



<p class="wp-block-paragraph">Appendix 2: The decision tree has been updated to reflect the revised expectations for filing nitrosamine risk mitigation-related changes.&nbsp;</p>



<p class="wp-block-paragraph">If you wish to understand how these changes might affect your business, please <a href="https://focalpointresearch.net/">reach out to us</a>.</p>
<p>The post <a href="https://focalpointresearch.net/canadian-regulatory/health-canada-updates-guidance-on-nitrosamine-impurities-in-medications/">Health Canada updates guidance on nitrosamine impurities in medications</a> appeared first on <a href="https://focalpointresearch.net">Focal Point</a>.</p>
]]></content:encoded>
					
		
		
		<post-id xmlns="com-wordpress:feed-additions:1">5866</post-id>	</item>
		<item>
		<title>Health Canada Extension on Nitrosamine Risk Assessments</title>
		<link>https://focalpointresearch.net/canadian-regulatory/health-canada-extension-on-nitrosamine-risk-assessments/</link>
		
		<dc:creator><![CDATA[Jenn Porter]]></dc:creator>
		<pubDate>Fri, 03 Apr 2020 20:38:26 +0000</pubDate>
				<category><![CDATA[Canadian Regulatory]]></category>
		<category><![CDATA[Medical Devices]]></category>
		<category><![CDATA[Natural Health Products]]></category>
		<category><![CDATA[Research/Science/Technology]]></category>
		<category><![CDATA[Health Canada consultants]]></category>
		<category><![CDATA[nitrosamine]]></category>
		<category><![CDATA[North American Scientific Regulatory Affairs & Quality Assurance Consulting Firm]]></category>
		<category><![CDATA[Scientific Regulatory & New Product Consultants]]></category>
		<guid isPermaLink="false">https://www.focalpointresearch.net/?p=4806</guid>

					<description><![CDATA[<p>Earlier this year, information about new regulations and requirements put in place by Health Canada for product’s containing nitrosamine impurities was released. These regulations are applicable to prescription and non-prescription pharmaceuticals containing chemically synthesized Active Pharmaceutical Ingredients (APIs). It was noted that Market Authorization Holders (MAHs) are responsible for testing their products to determine the [&#8230;]</p>
<p>The post <a href="https://focalpointresearch.net/canadian-regulatory/health-canada-extension-on-nitrosamine-risk-assessments/">Health Canada Extension on Nitrosamine Risk Assessments</a> appeared first on <a href="https://focalpointresearch.net">Focal Point</a>.</p>
]]></description>
										<content:encoded><![CDATA[
<p class="wp-block-paragraph">Earlier this year,<a rel="noreferrer noopener" href="https://focalpointresearch.net/canadian-regulatory/update-on-nitrosamine-impurities-in-pharmaceutical-products/" target="_blank"> information</a> about new regulations and requirements put in place by Health Canada for product’s containing nitrosamine impurities was released. These regulations are applicable to prescription and non-prescription pharmaceuticals containing chemically synthesized Active Pharmaceutical Ingredients (APIs). It was noted that Market Authorization Holders (MAHs) are responsible for testing their products to determine the presence of nitrosamine impurities. It is up to the MAH to determine what their products should be tested for, such as max daily dosage, duration of use, and considerations of specific populations, such as children and pregnant women. If the outcome of the tests indicates the product is safe, the results should be retained by the MAH. If any impurities are detected during testing, the MAH is required to inform Health Canada immediately to allow proper steps to be taken.</p>



<p class="wp-block-paragraph">In the original release of Health Canada’s letter, it was requested that the MAHs conduct these risk assessments for all their products within 6 months of the release of the letter to the public. This would have meant the MAHs had until April 2, 2020 to complete product risk assessments for all their synthesized Active Pharmaceutical Ingredients (APIs). The letter also requested that all confirmatory testing and any changes to the marketing authorizations be completed within two years, with a deadline of October 1, 2021. Now, as a result of the COVID-19 pandemic, Health Canada has provided an extension and has released an <a rel="noreferrer noopener" href="https://healthycanadians.gc.ca/recall-alert-rappel-avis/hc-sc/2019/71770a-eng.php" target="_blank">updated timeline.</a> The risk assessments now must be completed by <strong>October 1, 2020</strong> and confirmatory tests and any changes to the market authorization must be completed by <strong>October 1, 2022</strong>.</p>



<p class="wp-block-paragraph">For more information, please contact&nbsp;<a rel="noreferrer noopener" href="https://focalpointresearch.net/" target="_blank">Focal Point Research Inc.&nbsp;</a>We are leading North American&nbsp;<a rel="noreferrer noopener" href="https://focalpointresearch.net/services/regulatory-affairs/" target="_blank">Regulatory</a>&nbsp;and New Product Consultants for&nbsp;<a rel="noreferrer noopener" href="https://focalpointresearch.net/services/medical-devices/" target="_blank">Medical Devices</a>,&nbsp;<a rel="noreferrer noopener" href="https://focalpointresearch.net/services/natural-health-products/" target="_blank">Natural Health Products</a>,&nbsp;<a rel="noreferrer noopener" href="https://focalpointresearch.net/services/drugs/" target="_blank">OTC Drugs</a>,&nbsp;<a rel="noreferrer noopener" href="https://focalpointresearch.net/services/cosmetic-consultants/" target="_blank">Cosmetics,</a>&nbsp;and other&nbsp;<a rel="noreferrer noopener" href="https://focalpointresearch.net/services/consumer-products/" target="_blank">consumer products</a>&nbsp;regulated by&nbsp;<a rel="noreferrer noopener" href="https://focalpointresearch.net/services/health-canada-consultants/" target="_blank">Health Canada&nbsp;</a>and the&nbsp;<a rel="noreferrer noopener" href="https://focalpointresearch.net/services/fda-consulting/" target="_blank">U.S. FDA</a></p>



<p class="wp-block-paragraph">Emily Campbell</p>
<p>The post <a href="https://focalpointresearch.net/canadian-regulatory/health-canada-extension-on-nitrosamine-risk-assessments/">Health Canada Extension on Nitrosamine Risk Assessments</a> appeared first on <a href="https://focalpointresearch.net">Focal Point</a>.</p>
]]></content:encoded>
					
		
		
		<post-id xmlns="com-wordpress:feed-additions:1">4806</post-id>	</item>
	</channel>
</rss>
